Videos

Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

$Clinical Scenario: A 61-Year-Old Woman With Relapsed/Refractory Multiple Myeloma (R/R MM)$

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Bone Disease Prophylaxis in Patients With Transplant-Eligible NDMM

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with relapsed/refractory multiple myeloma for panel discussion.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Cross Q&A: Balancing Progression and Lines of Therapy at Myeloma Relapse

Expert panelists discuss the options for preventing bone disease in patients with multiple myeloma, including osteonecrosis of the jaw.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Navigating Biochemical Relapse and MRD Resurgence in Multiple Myeloma

Expert insights into tailoring treatment for biochemical relapse in multiple myeloma patients, considering disease progression and the impact of various therapy lines on treatment decisions.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety

An insightful discussion among specialists about the challenges of treating biochemical relapse and MRD resurgence in multiple myeloma patients, exploring nuanced considerations, patient collaboration, and the evolving landscape of treatment strategies.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study

Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Momelotinib Will ‘Make an Immediate Impact’ in Myelofibrosis With Anemia

An expert explores findings of the OPTIC study, revealing optimal dosing strategies for ponatinib in CML treatment, including insights into dose reduction and patient response based on T315I mutation status.

Ruben A. Mesa, MD, FACP

August 2023 Snap Recap: Chemo Shortages, FDA Approvals in Multiple Myeloma

With the approval of momelotinib by the FDA, the updated use for its role in myelofibrosis will potentially change clinical practice, according to Ruben Mesa, MD.

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

Hayley Virgil

Patient Scenario: A 65-Year-Old Man with HER2+ mCRC

The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

Common Testing Strategies for Molecular Markers in mCRC

Daniel Walden, MD, presents the scenario of a 65-year-old man diagnosed with HER2+ metastatic colorectal cancer to the expert panel for discussion.

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

Assessing Frailty in Multiple Myeloma

Experts emphasize the importance of acquiring both tissue and circulating tumor DNA (ctDNA) for molecular testing in patients with metastatic colorectal cancer, address challenges such as lack of tissue and costs, and highlight the role of HER2 as a biomarker.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Treatment Strategies for Patients With Transplant-Ineligible MM

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Factors for Consideration When Treating Frail Patients With Transplant-Ineligible NDMM

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Selecting Between DRd and VRd Combination Regimens for Patients With Transplant-Ineligible NDMM

Focused discussion on tailoring treatment decision-making for patients with multiple myeloma classified as frail.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

The Future of GVHD Treatment

A panel of experts explain how they select between the DRd (daratumumab, lenalidomide, dexamethasone) and VRd (bortezomib, lenalidomide, dexamethasone) treatment regimens for patients with transplant-ineligible newly diagnosed multiple myeloma.

Nelson J. Chao, MD, MBA

Biochemical and Clinical Progression: The Two Faces of Relapsed MM

The panel shares new therapies for the treatment of chronic graft-versus-host disease they look forward to seeing in the future.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope

Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.

Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Vivian G. Oehler, MD;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope

A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.

Vivian G. Oehler, MD;Andrew J. Cowan, MD;Rahul Banerjee, MD, FACP;Paul B. Koller, MD;Lawrence W. Liu, MD;Murali Janakiram, MD, MS

Evolving Treatment Landscape of RCC: Future Directions in Care

An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.

Brian I. Rini, MD;Moshe Ornstein, MD, MA;Elizabeth R. Plimack, MD, MS;Robert J. Motzer, MD

The Evolving Landscape of Biomarker Testing in Metastatic Colorectal Cancer (mCRC)

Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

September 8th 2023

Daniel Ahn, DO, discusses the evolution of biomarker testing in metastatic colorectal cancer, highlighting the shift from understanding only the prognostic implications of genetic alterations to recognizing their predictive role in targeted therapies, and emphasizes the potential of circulating tumor DNA for rapid diagnosis and assessing treatment response.

An Overview of Colorectal Cancer (CRC)

Tanios S. Bekaii-Saab, MD, FACP;Daniel Ahn, DO;Christina Wu, MB, BCh, MD;Daniel Walden, MD

September 8th 2023

Tanios Bekaii-Saab, MD, and colleagues address updates in metastatic colorectal cancer treatment, highlighting its prevalence in the U.S., the concerning rise in younger patients, and the ongoing uncertainty regarding the causes of this trend, with potential factors like environment and microbiome under investigation.

Transplant and Treatment Decision-Making in Multiple Myeloma

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Multiple Myeloma: Data on Outcomes Based On Cytogenetics

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Peter Voorhees, MD;Kwabena Osei-Boateng, MD;Amy Soni, MD;Reed Friend, MD

Clinical Scenario: A 68-Year-Old Man With Transplant-Ineligible NDMM

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS

Treatment Strategies for Patients With High-Risk NDMM

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 68-year-old man with transplant-ineligible newly diagnosed multiple myeloma to the expert panel for discussion.

Michael Rosenzweig, MD, MS;Ashwin Kashyap, MD;Neel Talwar, MD;Natasha Garg, DO, MS